[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

Chaudhury et al., 2018 - Google Patents

Age-specific biological and molecular profiling distinguishes paediatric from adult acute myeloid leukaemias

Chaudhury et al., 2018

View HTML @Full View
Document ID
18242763316438037258
Author
Chaudhury S
O’Connor C
Cañete A
Bittencourt-Silvestre J
Sarrou E
Prendergast Ã
Choi J
Johnston P
Wells C
Gibson B
Keeshan K
Publication year
Publication venue
Nature communications

External Links

Snippet

Acute myeloid leukaemia (AML) affects children and adults of all ages. AML remains one of the major causes of death in children with cancer and for children with AML relapse is the most common cause of death. Here, by modelling AML in vivo we demonstrate that AML is …
Continue reading at www.nature.com (HTML) (other versions)

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues ; Not used, see subgroups
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0647—Haematopoietic stem cells; Uncommitted or multipotent progenitors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES OR MICRO-ORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or micro-organisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or micro-organisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Hybridisation probes
    • C12Q1/6883—Hybridisation probes for diseases caused by alterations of genetic material
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay
    • G01N33/574—Immunoassay; Biospecific binding assay for cancer
    • G01N33/57407—Specifically defined cancers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology

Similar Documents

Publication Publication Date Title
Chaudhury et al. Age-specific biological and molecular profiling distinguishes paediatric from adult acute myeloid leukaemias
Stringer et al. A reference collection of patient-derived cell line and xenograft models of proneural, classical and mesenchymal glioblastoma
Bahr et al. A Myc enhancer cluster regulates normal and leukaemic haematopoietic stem cell hierarchies
Park et al. IKZF2 drives leukemia stem cell self-renewal and inhibits myeloid differentiation
Will et al. Minimal PU. 1 reduction induces a preleukemic state and promotes development of acute myeloid leukemia
Vu et al. Functional screen of MSI2 interactors identifies an essential role for SYNCRIP in myeloid leukemia stem cells
Kode et al. Leukaemogenesis induced by an activating β-catenin mutation in osteoblasts
Jarjour et al. Bhlhe40 mediates tissue-specific control of macrophage proliferation in homeostasis and type 2 immunity
Netherby et al. The granulocyte progenitor stage is a key target of IRF8-mediated regulation of myeloid-derived suppressor cell production
Zhang et al. Sox4 is a key oncogenic target in C/EBPα mutant acute myeloid leukemia
Volk et al. A CHAF1B-dependent molecular switch in hematopoiesis and leukemia pathogenesis
Meyer et al. DNMT3A haploinsufficiency transforms FLT3 ITD myeloproliferative disease into a rapid, spontaneous, and fully penetrant acute myeloid leukemia
Venkatraman et al. Maternal imprinting at the H19–Igf2 locus maintains adult haematopoietic stem cell quiescence
Will et al. Satb1 regulates the self-renewal of hematopoietic stem cells by promoting quiescence and repressing differentiation commitment
Cabal-Hierro et al. Chromatin accessibility promotes hematopoietic and leukemia stem cell activity
Klinakis et al. A novel tumour-suppressor function for the Notch pathway in myeloid leukaemia
Huang et al. Neutralizing negative epigenetic regulation by HDAC5 enhances human haematopoietic stem cell homing and engraftment
Rathinam et al. Myeloid leukemia development in c-Cbl RING finger mutant mice is dependent on FLT3 signaling
Uni et al. Modeling ASXL1 mutation revealed impaired hematopoiesis caused by derepression of p16Ink4a through aberrant PRC1-mediated histone modification
Micol et al. ASXL2 is essential for haematopoiesis and acts as a haploinsufficient tumour suppressor in leukemia
Blackburn et al. Notch signaling expands a pre-malignant pool of T-cell acute lymphoblastic leukemia clones without affecting leukemia-propagating cell frequency
Chen et al. MLL-AF9 initiates transformation from fast-proliferating myeloid progenitors
Hyrenius-Wittsten et al. De novo activating mutations drive clonal evolution and enhance clonal fitness in KMT2A-rearranged leukemia
Hoang et al. The rarity of ALDH+ cells is the key to separation of normal versus leukemia stem cells by ALDH activity in AML patients
Niebuhr et al. Runx1 is essential at two stages of early murine B-cell development